Immunomedics Awarded Key Patent for TROP-2 Antibody

barbara.lempert MORRIS PLAINS, N.J., Nov. 5, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal ...

Bristol-Myers to ax up to 75 R&D staffers, halting discovery work in three fields

John Carroll Bristol-Myers Squibb joined the lineup of biopharma companies executing R&D realignments today, announcing plans to cut back on some of its discovery work ...

Gastro specialist Salix nabs Santarus and new colitis drug in $2.6B deal

Tracy Staton FiercePharma News

Karyopharm joins biotech’s fall IPO parade with $109M haul

John Carroll Karyopharm joined the Q4 biotech IPO parade today, pricing its shares at the top of the range and hauling in $ 104 million on an upsized batch of 6.8 million shares–a ...

Will Merck be next to join Big Pharma’s asset-sale parade?

Tracy Staton Novartis and Pfizer are in the process of spinning off units. Abbott Laboratories set its pharma business free at the beginning of this year. Why wouldn't Merck decide ...

Catalyst Pharma Fights Greed Charges Over An Orphan Drug

esilverman For the past month, shares in a small developer of novel drugs called Catalyst Pharmaceutical Partners have given up roughly half their value amid an unusual public ...

Eli Lilly spells out $1.8B deal to partner with Pfizer on tanezumab

John Carroll When Pfizer first let slip that it struck a deal to collaborate with Eli Lilly on the high-risk anti-NGF pain drug tanezumab, the news was delivered without any of the ...

JAMA study raises red flag on big-selling testosterone drugs

Tracy Staton As more and more baby boomers have signed on for testosterone testing–and, in turn, therapy–worries about the safety of testosterone-boosting drugs have ...

With Qsymia still flailing, Vivus to cut 20 jobs, replace CFO

Tracy Staton Vivus says it's laying off 20 staffers to cut its losses as the obesity drug Qsymia continues to flounder. Launched last year, Qsymia brought in just $ 6.4 million ...

Supernus Announces Release of New Clinical Data on Trokendi XR

barbara.lempert Supernus Announces Release of Exciting New Clinical Data on Trokendi XR(TM) ROCKVILLE, Md., Nov. 6, 2013 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), ...

PDL injects $70M into Durata; Vivus to cut 20 staffers; FDA outlines proper use of Iclusig

John Carroll FierceBiotech News

UK And Pharma Reach Deal To Cap Prices, But Bitterness Remains

esilverman For the first time, the UK has instituted a pricing policy on brand-name prescription drugs that comes with a cap. Under the five-year plan, the Pharmaceutical Price ...
Page 5 of 8« First...34567...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS